Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00394745 |
The purpose of this study is to evaluate potential effects of valsartan on lipid subfractions and other parameters in lipid metabolism in patients with essential hypertension and metabolic syndrome.
Condition | Intervention | Phase |
---|---|---|
Hypertension Metabolic Syndrome |
Drug: Valsartan |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A 12 Week Treatment, Open-Label, Multicenter Study to Investigate the Efficacy and Safety of Valsartan 160-320 mg With Regard to Effects on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome |
Estimated Enrollment: | 50 |
Study Start Date: | November 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CVAL489ADE25 |
Study First Received: | October 31, 2006 |
Last Updated: | July 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00394745 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Hypertension, Metabolic Syndrome, lipid subfractions |
Vascular Diseases Cardiovascular Agents Antihypertensive Agents Valsartan Hypertension |
Pathologic Processes Disease Therapeutic Uses Syndrome Vascular Diseases Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Valsartan Hypertension |